

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION

GALDERMA LABORATORIES, L.P.,  
GALDERMA S.A., and  
GALDERMA RESEARCH &  
DEVELOPMENT, S.N.C.,

Plaintiffs,

v.

TARO PHARMACEUTICALS U.S.A.,  
INC.,

Defendant.

§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§

CIVIL ACTION NO. \_\_\_\_\_

**COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiffs, GALDERMA LABORATORIES, L.P., GALDERMA S.A., and GALDERMA RESEARCH & DEVELOPMENT, S.N.C., file this Complaint for Patent Infringement against Defendant TARO PHARMACEUTICALS U.S.A., INC. and state as follows:

**PARTIES**

1. Galderma Laboratories, L.P. ("Galderma L.P.") is a Texas limited partnership with its principal place of business at 14501 North Freeway, Fort Worth, Texas 76177. Galderma L.P. is the beneficial holder of rights to market Epiduo<sup>®</sup> (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5% (hereafter, "Epiduo<sup>®</sup> Gel") under FDA approval of New Drug Application No. 022320, approved December 8, 2008. Galderma L.P. has the exclusive right from Galderma Research & Development, S.N.C. ("Galderma R&D") to distribute Epiduo<sup>®</sup> Gel in the United States. Epiduo<sup>®</sup> Gel is a topical ointment prescription drug that combines a retinoid (adapalene) and an antimicrobial (benzoyl peroxide) for the treatment of acne vulgaris (severe acne) in people who are at least 9 years old.

2. Galderma S.A. is a Swiss company with its principal place of business at World Trade Center, Avenue de Gratta-Paille 2, 1018 Lausanne, Switzerland. Galderma S.A. and/or its affiliates are involved in the research, development, marketing, and sale of pharmaceutical products.

3. Galderma R&D is a French corporation with its principal place of business at 2400 Route Des Colles, Les Templiers, Biot, France 06410. Galderma R&D is the current owner of U.S. Patent No. 8,071,644 (the "'644 Patent"), U.S. Patent No. 8,080,537 (the "'537 Patent"), U.S. Patent No. 8,129,362 (the "'362 Patent"), U.S. Patent No. 8,445,543 (the "'543 Patent"), and U.S. Patent No. 8,809,305 (the "'305 Patent"). A copy of the '644 Patent is attached as Exhibit "A." A copy of the '537 Patent is attached as Exhibit "B." A copy of the '362 Patent is attached as Exhibit "C." A copy of the '543 Patent is attached as Exhibit "D." A copy of the '305 Patent is attached as Exhibit "E."

4. Taro Pharmaceuticals U.S.A., Inc. ("Taro") is a corporation organized and existing under the laws of the State of New York with its principal place of business at 3 Skyline Drive, Hawthorne, New York, 10532. Taro may be served with process by and through its registered agent for service of process, C T Corporation System, 111 Eighth Avenue, New York, New York, 10011.

#### **JURISDICTION AND VENUE**

5. This is a complaint for patent infringement. This Court has jurisdiction over the subject matter of the claims asserted pursuant to 28 U.S.C. §§ 1331 and 1338(a). Venue in this Court is proper under 28 U.S.C. §§ 1391 and 1400(b).

6. This Court has personal jurisdiction over Taro because Taro sells products for distribution throughout the United States and, on information and belief, regularly conducts

business in the State of Texas. Taro also submitted the ANDA (an act of infringement under 35 U.S.C. § 271(e)(2)) for the infringing product and issued a certification under 21 U.S.C. § 355(j)(2)(B) (the "Paragraph IV Certification")—the acts which give rise to the instant litigation—with knowledge that Galderma L.P. would be injured by such actions in this district, and delivered its Paragraph IV Certification to Galderma L.P. in this district. Moreover, on information and belief, Taro intends to sell the infringing product in or for distribution in this district upon approval by the FDA. Taro has thus purposefully targeted its conduct to cause harm in the State of Texas and this district.

7. Venue is proper in this district because the claims asserted herein arise out of an act of patent infringement (*i.e.*, Taro's submission of the ANDA and issuance of the Paragraph IV Certification) purposefully targeting a resident of this district (*i.e.*, Galderma L.P.). Further, venue is proper in this district because 21 U.S.C. § 355(j)(5)(C)(i)(II) establishes this district as the only proper venue in which Taro could file suit seeking a declaration of non-infringement in connection with the ANDA.

### **BACKGROUND FACTS**

#### **A. The '644 Patent**

8. On December 6, 2011, the USPTO issued the '644 Patent, entitled "Combinations of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," to Galderma R&D.

9. The '644 Patent is valid, enforceable, and has not expired.

#### **B. The '537 Patent**

10. On December 20, 2011, the USPTO issued the '537 Patent, entitled "Combinations of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," to Galderma R&D.

11. The '537 Patent is valid, enforceable, and has not expired.

**C. The '362 Patent**

12. On March 6, 2012, the USPTO issued the '362 Patent, entitled "Combination/ Association of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," to Galderma R&D.

13. The '362 Patent is valid, enforceable, and has not expired.

**D. The '543 Patent**

14. On May 21, 2013, the USPTO issued the '543 Patent, entitled "Combinations of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," to Galderma R&D.

15. The '543 Patent is valid, enforceable, and has not expired.

**E. The '305 Patent**

16. On August 19, 2014, the USPTO issued the '305 Patent, entitled "Administration of Adapalene and Benzoyl Peroxide for the Long-Term Treatment of Acne Vulgaris," to Galderma R&D.

17. The '305 Patent is valid, enforceable, and has not expired.

**F. Epiduo<sup>®</sup> Gel**

18. Galderma L.P. is the holder of New Drug Application ("NDA") No. 022320. On December 8, 2008, Galderma L.P. obtained FDA Approval to market Epiduo<sup>®</sup> Gel. The '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent are listed in the FDA publication entitled "Approved Drug Products With Therapeutic Equivalence Evaluations" (known as the "Orange Book") as covering Epiduo<sup>®</sup> (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%.

19. Galderma S.A. and Galderma R&D have granted Galderma L.P. the exclusive right to distribute Epiduo<sup>®</sup> Gel in the United States.

**G. Taro's Infringement**

20. Taro is in the business of developing, manufacturing, and marketing generic pharmaceutical products.

21. On information and belief, Taro reviewed the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent and certain commercial and economic information relating to Epiduo<sup>®</sup> Gel, including estimates of the revenues generated by the sale of Epiduo<sup>®</sup> Gel.

22. Taro submitted Abbreviated New Drug Application No. 206959 (the "ANDA") seeking approval to engage in the commercial manufacture, use, and sale of generic Adapalene and Benzoyl Peroxide Gel, 0.1% / 2.5% ("the Accused Product") prior to the expiration of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent.

23. The Accused Product that is the subject of the ANDA directly and indirectly infringes one or more claims of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent.

24. On or about July 14, 2015, Taro sent a letter (the "Certification Letter") to Galderma L.P. in Fort Worth, Texas, and to Galderma R&D in France. Through the Certification Letter, Taro first notified Plaintiffs that Taro had filed the ANDA with the FDA relating to the Accused Product and that the ANDA includes a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (a "Paragraph IV certification") that, in Taro's opinion, the claims of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, offer for sale, sale, or importation of the Accused Product.

25. Taro was aware of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent when it filed the ANDA and/or sent the Certification Letter.

26. Plaintiffs have commenced this action within 45 days of the date that they received Taro's notice of the ANDA containing the Paragraph IV certification.

27. On information and belief, Taro intends to continue seeking approval of the ANDA from the FDA, and to engage in the commercial manufacture, marketing, and sale of the Accused Product (including commercial marketing and sale of the Accused Product in the State of Texas, including this District), in the event that FDA approves the ANDA.

**COUNT I:**  
**INFRINGEMENT OF U.S. PATENT NO. 8,071,644**

28. Plaintiffs incorporate paragraphs 1 through 27 above by reference as if fully set forth herein.

29. The '644 Patent is valid, enforceable, and has not expired.

30. The Accused Product and/or its use as directed infringes one or more of the claims of the '644 Patent. As such, under 35 U.S.C. § 271(e)(2)(A), Taro infringed the '644 Patent by submitting the ANDA seeking permission to commercially manufacture, use, or sell the Accused Product prior to the expiration of the '644 Patent.

31. On information and belief, Taro will induce infringement of one or more claims of the '644 Patent—in violation of Plaintiffs' patent rights—if the FDA approves the sale of the Accused Product with instructions and labeling that will result in direct infringement of one or more claims of the '644 Patent by users of the Accused Product.

32. On information and belief, Taro seeks approval of at least one indication for the Accused Product that is claimed in the '644 Patent.

33. On information and belief, Taro knows that physicians will prescribe, and patients will use, the Accused Product in accordance with the indication(s) sought by Taro and will therefore infringe one or more claims of the '644 Patent under 35 U.S.C. § 271(b).

34. Plaintiffs will be substantially and irreparably harmed by Taro's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

35. As a result of Taro's infringement, Plaintiffs are entitled to a declaration that the Accused Product infringes the '644 Patent if made, used as directed, sold, offered for sale, or imported during the term of the '644 Patent.

36. As a result of Taro's infringement, Plaintiffs are entitled to permanent injunctive relief, restraining and enjoining Taro and all those in privity with or acting in concert with Taro from manufacturing, selling, offering to sell, or importing the Accused Product during the term of the '644 Patent, or from otherwise infringing or inducing the infringement of the '644 Patent.

**COUNT II:**  
**INFRINGEMENT OF U.S. PATENT NO. 8,080,537**

37. Plaintiffs incorporate paragraphs 1 through 36 above by reference as if fully set forth herein.

38. The '537 Patent is valid, enforceable, and has not expired.

39. The Accused Product and/or its use as directed infringes one or more of the claims of the '537 Patent. As such, under 35 U.S.C. § 271(e)(2)(A), Taro infringed the '537 Patent by submitting the ANDA seeking permission to commercially manufacture, use, or sell the Accused Product prior to the expiration of the '537 Patent.

40. On information and belief, Taro will induce infringement of one or more claims of the '537 Patent—in violation of Plaintiffs' patent rights—if the FDA approves the sale of the Accused Product with instructions and labeling that will result in direct infringement of one or more claims of the '537 Patent by users of the Accused Product.

41. On information and belief, Taro seeks approval of at least one indication for the Accused Product that is claimed in the '537 Patent.

42. On information and belief, Taro knows that physicians will prescribe, and patients will use, the Accused Product in accordance with the indication(s) sought by Taro and will therefore infringe one or more claims of the '537 Patent under 35 U.S.C. § 271(b).

43. Plaintiffs will be substantially and irreparably harmed by Taro's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

44. As a result of Taro's infringement, Plaintiffs are entitled to a declaration that the Accused Product infringes the '537 Patent if made, used as directed, sold, offered for sale, or imported during the term of the '537 Patent.

45. As a result of Taro's infringement, Plaintiffs are entitled to permanent injunctive relief, restraining and enjoining Taro and all those in privity with or acting in concert with Taro from manufacturing, selling, offering to sell, or importing the Accused Product during the term of the '537 Patent, or from otherwise infringing or inducing the infringement of the '537 Patent.

**COUNT III:**  
**INFRINGEMENT OF U.S. PATENT NO. 8,129,362**

46. Plaintiffs incorporate paragraphs 1 through 45 above by reference as if fully set forth herein.

47. The '362 Patent is valid, enforceable, and has not expired.

48. The Accused Product and/or its use as directed infringes one or more of the claims of the '362 Patent. As such, under 35 U.S.C. § 271(e)(2)(A), Taro infringed the '362 Patent by submitting the ANDA seeking permission to commercially manufacture, use, or sell the Accused Product prior to the expiration of the '362 Patent.



49. On information and belief, Taro will induce infringement of one or more claims of the '362 Patent—in violation of Plaintiffs' patent rights—if the FDA approves the sale of the Accused Product with instructions and labeling that will result in direct infringement of one or more claims of the '362 Patent by users of the Accused Product.

50. On information and belief, Taro seeks approval of at least one indication for the Accused Product that is claimed in the '362 Patent.

51. On information and belief, Taro knows that physicians will prescribe, and patients will use, the Accused Product in accordance with the indication(s) sought by Taro and will therefore infringe one or more claims of the '362 Patent under 35 U.S.C. § 271(b).

52. Plaintiffs will be substantially and irreparably harmed by Taro's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

53. As a result of Taro's infringement, Plaintiffs are entitled to a declaration that the Accused Product infringes the '362 Patent if made, used as directed, sold, offered for sale, or imported during the term of the '362 Patent.

54. As a result of Taro's infringement, Plaintiffs are entitled to permanent injunctive relief, restraining and enjoining Taro and all those in privity with or acting in concert with Taro from manufacturing, selling, offering to sell, or importing the Accused Product during the term of the '362 Patent, or from otherwise infringing or inducing the infringement of the '362 Patent.

**COUNT IV:**  
**INFRINGEMENT OF U.S. PATENT NO. 8,445,543**

55. Plaintiffs incorporate paragraphs 1 through 54 above by reference as if fully set forth herein.

56. The '543 Patent is valid, enforceable, and has not expired.

57. The Accused Product and/or its use as directed infringes one or more of the claims of the '543 Patent. As such, under 35 U.S.C. § 271(e)(2)(A), Taro infringed the '543 Patent by submitting the ANDA seeking permission to commercially manufacture, use, or sell the Accused Product prior to the expiration of the '543 Patent.

58. Upon information and belief, Taro will induce infringement of one or more claims of the '543 Patent—in violation of Plaintiffs' patent rights—if the FDA approves the sale of the Accused Product with instructions and labeling that will result in direct infringement of one or more claims of the '543 Patent by users of the Accused Product.

59. On information and belief, Taro seeks approval of at least one indication for the Accused Product that is claimed in the '543 Patent.

60. On information and belief, Taro knows that physicians will prescribe, and patients will use, the Accused Product in accordance with the indication(s) sought by Taro and will therefore infringe one or more claims of the '543 Patent under 35 U.S.C. § 271(b).

61. Plaintiffs will be substantially and irreparably harmed by Taro's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

62. As a result of Taro's infringement, Plaintiffs are entitled to a declaration that the Accused Product infringes the '543 Patent if made, used as directed, sold, offered for sale, or imported during the term of the '543 Patent.

63. As a result of Taro's infringement, Plaintiffs are entitled to permanent injunctive relief, restraining and enjoining Taro and all those in privity with or acting in concert with Taro from manufacturing, selling, offering to sell, or importing the Accused Product during the term of the '543 Patent, or from otherwise infringing or inducing the infringement of the '543 Patent.

**COUNT V:**  
**INFRINGEMENT OF U.S. PATENT NO. 8,809,305**

64. Plaintiffs incorporate paragraphs 1 through 63 above by reference as if fully set forth herein.

65. The '305 Patent is valid, enforceable, and has not expired.

66. In at least some circumstances, use of the Accused Product and/or its use as directed infringes one or more of the claims of the '305 Patent. As such, under 35 U.S.C. § 271(e)(2)(A), Taro infringed the '305 Patent by submitting the ANDA seeking permission to commercially manufacture, use, or sell the Accused Product prior to the expiration of the '305 Patent.

67. On information and belief, Taro will induce infringement of one or more claims of the '305 Patent—in violation of Plaintiffs' patent rights—if the FDA approves the sale of the Accused Product with instructions and labeling that will result in direct infringement of one or more claims of the '305 Patent by users of the Accused Product.

68. On information and belief, Taro seeks approval of the Accused Product that will result in infringement of methods claimed in the '305 Patent.

69. On information and belief, Taro knows that physicians will prescribe, and patients will use, the Accused Product in accordance with the methods claimed in the '305 Patent under 35 U.S.C. § 271(b).

70. Plaintiffs will be substantially and irreparably harmed by Taro's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

71. As a result of Taro's infringement, Plaintiffs are entitled to a declaration that the Accused Product infringes the '305 Patent if made, used as directed, sold, offered for sale, or imported during the term of the '305 Patent.

72. As a result of Taro's infringement, Plaintiffs are entitled to permanent injunctive relief, restraining and enjoining Taro and all those in privity with or acting in concert with Taro from manufacturing, selling, offering to sell, or importing the Accused Product during the term of the '305 Patent, or from otherwise infringing or inducing the infringement of the '305 Patent.

### **DEMAND FOR JURY TRIAL**

In the event Taro commercially manufactures, uses, sells, offers to sell, or imports the Accused Product prior to trial, Plaintiffs demand trial by jury of all issues and claims alleged herein.

### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray for the following relief:

(A) A declaration that Taro's commercial manufacture, use, offer for sale, or sale in, or importation into the United States of the Accused Product prior to the date of the expiration of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent including any patent extensions and any additional periods of exclusivity, would constitute infringement of such patents in violation of Plaintiffs' patent rights;

(B) A declaration, pursuant to 35 U.S.C. § 271(e)(2)(A), that Taro has infringed the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent by submitting the ANDA to the FDA to obtain approval to commercially manufacture, use, offer for sale, sell in, or import into the United States the Accused Product prior to the expiration of such patents, including any

patent extensions and any additional periods of exclusivity, and that the Accused Product infringes such patents;

(C) An order, pursuant to 35 U.S.C. § 271(e)(4)(A), that the effective date of any approval of the Accused Product described in the ANDA is not to be earlier than the date of the expiration of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent including any patent extensions and any additional periods of exclusivity;

(D) A permanent injunction, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and (D), and 35 U.S.C. § 283, enjoining Taro and its officers, agents, servants, employees, privies, and others acting for, on behalf of, or in concert with any of them, from commercially manufacturing, using, selling, or offering to sell the Accused Product within the United States; importing the Accused Product into the United States; or otherwise infringing or inducing the infringement of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent, prior to the date of the expiration of such patents, including any patent extensions and any additional periods of exclusivity;

(E) An award to Plaintiffs, pursuant to 35 U.S.C. § 271(e)(4)(C), of damages and other monetary relief, as a result of Taro's infringement, to the extent there has been any commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of the Accused Product prior to the date of the expiration of the '644 Patent, '537 Patent, '362 Patent, '543 Patent, and '305 Patent, including any patent extensions and any additional periods of exclusivity; and

(F) Such other and further relief as this Court may deem just and proper.

Respectfully submitted,

*/s/ Michael C. Wilson*

---

Michael C. Wilson  
Texas State Bar No. 21704590  
mwilson@munckwilson.com  
Jamil N. Alibhai  
Texas State Bar No. 00793248  
jalibhai@munckwilson.com  
Daniel E. Venglarik  
Texas State Bar No. 00791851  
dvenglarik@munckwilson.com  
Kelly P. Chen  
Texas State Bar No. 24062664  
kchen@munckwilson.com  
Jordan C. Strauss  
Texas State Bar No. 24088480  
jstrauss@munckwilson.com  
**MUNCK WILSON MANDALA, LLP**  
600 Banner Place Tower  
12770 Coit Road  
Dallas, Texas 75251  
Telephone: 972-628-3600  
Facsimile: 972-628-3616

**ATTORNEYS FOR PLAINTIFFS  
GALDERMA LABORATORIES, L.P.,  
GALDERMA S.A., AND GALDERMA  
RESEARCH & DEVELOPMENT, S.N.C.**

665162.